Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have
Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have been encouraging, according to the company. Code 7228, a proprietary coated iron oxide compound, is being groomed for cardiovascular applications.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.